October 21, 1997, James P. Love, "Health Registration Data Exclusivity, Biomedical Research, and Restrictions on the Introduction of Generic Drugs," Prepared Testimony, U.S. Senate, Committee on Appropriations, Subcommittee on Labor, Health and Human Services and Education and Related Agencies. ( http://www.cptech.org/pharm/senhregd.html)

October 6, 1997, James Love, "the Medicines and Related Substances Control Amendment Bill and South African Reform of Pharmaceutical Policies," Comments of the Consumer Project on Technology to the Portfolio Committee on Health, South African Parliament, Cape Town, South Africa. (http://www.cptech.org/pharm/sa/sa-10-97.html)

May 1997, James Love, "A Free Trade Area For The Americas: A Consumer Perspective On Proposals As They Relate To Rules Regarding Intellectual Property," Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16, 1997. (http://www.cptech.org/pharm/belopaper.html)

January 13, 1997, James Love, "Call for More Reliable Costs Data on Clinical Trials," Marketletter, pages 24-5. (http://www.cptech.org/pharm/marketletter.html)

October 4, 1996, James Love, "Comments on Trade and Pharmaceutical Policies: A Perspective from the U.S. Consumer Movement," Comments at HAI Seminar on the World Trade Organization, GATT, Pharmaceutical Policies and Essential Drugs, at Bielefeld, Germany. (http://www.cptech.org/pharm/bielefeld.html)

December 1994, James Love, "Pricing of Drugs Developed with Public Funds: Comments Presented to the Second NIH CRADA Forum," in Reports of the NIH Panels on Cooperative Research and Development Agreements: Perspective, Outlook and Policy Development, National Institutes of Health. (http://www.cptech.org/pharm/crada2.html)

July 27, 1994, James Love, "Prepared Statement of James P. Love," in United States Senate, Committee on Governmental Affairs, Drug Pricing: Poor Prescription for Consumers and Taxpayers, S. Hrg. 103-1045.

July 11, 1994, James Love, "Comments on the Need for Better Federal Government Oversight of Taxpayer Supported Research and Development," included in U.S. House of Representatives, Committee on Small Business, Subcommittee on Regulation, Business Opportunities and Technology, Underreporting Federal Involvement in New Technologies Developed At Scripps Research Institute, Serial No. 103-93.

May 1994, James Packard Love, "Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States, Presented at XV Asamblea General de la Asociaión Latinoamericana de Industrias Farmacéuticas, San Carlos de Bariloche - Río Negro – Argentina, 11 al 13 de mayo de 1994. (http://www.cptech.org/pharm/bariloche.html)

February 8, 1994, James Love, "Prescription Drug Benefits and The Clinton Health Care Plan," included in U.S. House of Representatives, Committee on Energy and Commerce, Subcommittee on Health and the Environment, Health Care Reform: Part 9, Serial No. 103-110. (http://www.cptech.org/pharm/waxman.html)

August 1993, Ralph Nader and James Love: "Don't Give Away U.S.-Funded Research," The Journal of NIH Research, Vol. 5.

Summer 1993, James Love, "The Other Drug War, How Industry Exploits Pharm Subsidies," The American Prospect, No. 14.

February 24, 1993, Ralph Nader and James Love, "Federally Funded Pharmaceutical Inventions," testimony before United States Senate, Special Committee on the Aging. (http://www.cptech.org/pharm/pryor.html).

January 25, 1993, "Private Sector Pricing of Taxol and Other Pharmaceutical Inventions Developed with Federal Funding," included in U.S. House of Representatives, Committee on Small Business, Subcommittee on Regulation, Business Opportunities, and Technology, Pricing of Drugs Codeveloped by Federal Laboratories and Private Companies, Serial No. 103-2.

January 21, 1992, James Love, "Comments on the Orphan Drug Act and Government Sponsored Monopolies for Marketing Pharmaceutical Drugs," included in United States Senate, Committee on the Judiciary, Subcommittee on Antitrust, Monopolies and Business Rights, Anticompetitive Abuse of the Orphan Drug Act: Invitation to High Prices, Serial Number J-102-48, pages 259-283.

July 29, 1991, James Love, "The National Cancer Institute’s Cooperative Research and Development Agreement (CRADA) with Bristol-Myers Squibb for the development of the drug taxol," included in U.S. House of Representatives, Committee on Small Business, Subcommittee on Regulation, Business Opportunities, and Energy, Exclusive Agreements between Federal Agencies and Bristol-Myers Squibb Co. for Drug Development. Serial No. 102-35.

May 8, 1991, James Love, "Statement of James Love," U.S. House of Representatives, Committee on Judiciary, Subcommittee on Courts, Intellectual Property, and the Administration of Justice, Reauthorization of the Patent and Trademark Office, U.S. Department of Commerce, dealing in part of with the need for better reporting of government’s role in funding patented inventions. Serial No. 53.